---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-016423"
form_type: "8-K"
ticker: "ZBH"
cik: "0001136869"
company_name: "ZIMMER BIOMET HOLDINGS, INC."
filed_at: "2023-05-02T23:59:59+00:00"
generated_at: "2026-06-16T02:40:52.624474+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Zimmer Biomet Q1 net sales $1.831B (+10.1% reported, +13.2% CC); raises FY2023 guidance

## Summary
- Q1 diluted EPS $1.11 GAAP, adjusted $1.89; net earnings $232.5M GAAP, $396.8M adjusted.
- U.S. knee sales $448.2M (+18.1% YoY); hip sales $252.3M (+12.3% YoY).
- Raises FY2023 adjusted EPS guidance to $7.40-$7.50 (prior $6.95-$7.15); reported revenue growth 5.0-6.0% (prior 1.5-3.5%).
- Completed acquisition of Embody, Inc., adding collagen-based biointegrative solutions to sports medicine.
- Launched Persona OsseoTi Keel Tibia for cementless knee replacement; ZBEdge platform enhancements at AAOS 2023.

## SEC filing metadata
- accession: 0000950170-23-016423
- form_type: 8-K
- ticker: ZBH
- cik: 0001136869
- company_name: ZIMMER BIOMET HOLDINGS, INC.
- filed_at: 2023-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1136869/000095017023016423/0000950170-23-016423-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1136869/000095017023016423/zbh-20230502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-016423
- JSON: https://secwatch.observer/filing/0000950170-23-016423.json
- Plain text: https://secwatch.observer/filing/0000950170-23-016423.txt

## Key facts
- Earnings Releases
  ZIMMER BIOMET HOLDINGS, INC. reported first quarter ended March 31, 2023 results: revenue $1.831 billion, net income $232.5 million, EPS $1.11.
  - Period: first quarter ended March 31, 2023
  - Revenue: $1.831 billion
  - Net income: $232.5 million
  - EPS: $1.11
  - Result: reported results
  source text: The Company reported first quarter net sales of $1.831 billion, an increase of 10.1% over the prior year period, and an increase of 13.2% on a constant currency 1 basis. Net earnings for the first quarter were $232.5 million, or $396.8 million on an adjusted 1 basis. Diluted earnings per share were $1.11 for the first quarter, and adjusted 1 diluted earnings per share were $1.89.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1136869/000095017023016423/0000950170-23-016423-index.htm
- Earnings Releases
  ZIMMER BIOMET HOLDINGS, INC. reported full-year 2023 results: EPS $7.40 - $7.50. Guidance raised.
  - Period: full-year 2023
  - EPS: $7.40 - $7.50
  - Guidance: raised
  - Result: guidance update
  source text: Projected Year Ending December 31, 2023 Previous Guidance Updated Guidance 2023 Reported Revenue Change 1.5% - 3.5% 5.0% - 6.0% Foreign Currency Exchange Impact (1.5)% (1.0)% Adjusted Diluted EPS (1) $6.95 - $7.15 $7.40 - $7.50
  evidence_url: https://www.sec.gov/Archives/edgar/data/1136869/000095017023016423/0000950170-23-016423-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.